BRIEF-Five Prime Announces Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free And Overall Survival Benef

Nov 10 (Reuters) - Five Prime Therapeutics Inc :
* FIVE PRIME ANNOUNCES BEMARITUZUMAB PLUS CHEMOTHERAPY DEMONSTRATES SIGNIFICANT PROGRESSION-FREE AND OVERALL SURVIVAL BENEFIT COMPARED TO PLACEBO PLUS CHEMOTHERAPY IN FRONT-LINE ADVANCED GASTRIC AND GASTROESOPHAGEAL JUNCTION CANCER
* FIVE PRIME THERAPEUTICS INC - ALL 3 EFFICACY ENDPOINTS IN GLOBAL PHASE 2 FIGHT TRIAL MET PRE-SPECIFIED STATISTICAL SIGNIFICANCE
* FIVE PRIME THERAPEUTICS INC - MEDIAN PROGRESSION-FREE SURVIVAL IMPROVED FROM 7.4 MONTHS TO 9.5 MONTHS IN PHASE 2 FIGHT TRIAL
* FIVE PRIME THERAPEUTICS INC - OVERALL RESPONSE RATE (ORR) IMPROVED BY 13.1% (P=0.106) IN PHASE 2 FIGHT TRIAL

Source text for Eikon: Further company coverage:

((reuters.briefs@thomsonreuters.com;)